Books > Medicine > Clinical & internal medicine > Dermatology
|
Buy Now
New Skin Toxicities for New Anticancer Therapies (Paperback)
Loot Price: R3,604
Discovery Miles 36 040
|
|
New Skin Toxicities for New Anticancer Therapies (Paperback)
Expected to ship within 12 - 17 working days
|
Targeted cancer therapies have revolutionised the therapeutic
management of many neoplasms, modifying patients' prognosis and
overall survival. These drugs block the cancer's growth and spread
by interfering with specific molecules which play a crucial role in
the proliferation, differentiation and survival of cancer cells.
Targeted therapies act selectively on specific molecular targets
related to cancers, whereas most of the conventional chemotherapies
act on all rapidly dividing normal and neoplastic cells. Moreover,
targeted therapies are often cytostatic and non-cytotoxic as
standard chemotherapies. Taken together, these aspects appear
important in reducing systemic toxicity and ensuring an improved
safety profile. The inhibition of epidermal growth factor receptor
(EGFR), vascular growth factor (VEGF) and BRAF represents major
achievements in research and development of solid tumour's
epithelial therapy. This class of biologics is currently widely
used in the treatment of metastatic and unresponsive neoplasms of
the colon, pancreas, lung, (NSCLC), breast, head and neck and
melanoma. This book aims to emphasize skin toxicity associated with
EGFR-, VEGF- and BRAF- inhibitors, focusing particularly on their
clinical presentation, histopathological findings, and specific
therapeutic options.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.